nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—liver cancer	0.274	1	CbGaD
Canagliflozin—UGT1A9—Sorafenib—liver cancer	0.19	0.451	CbGbCtD
Canagliflozin—ABCC2—Sorafenib—liver cancer	0.0947	0.225	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—liver cancer	0.0574	0.136	CbGbCtD
Canagliflozin—ABCC2—bile canaliculus—liver cancer	0.0423	0.454	CbGeAlD
Canagliflozin—ABCB1—Sorafenib—liver cancer	0.0309	0.0732	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—liver cancer	0.0187	0.0444	CbGbCtD
Canagliflozin—CYP3A4—Sorafenib—liver cancer	0.0185	0.0439	CbGbCtD
Canagliflozin—ABCC2—bile duct—liver cancer	0.0132	0.142	CbGeAlD
Canagliflozin—ORM1—bile—liver cancer	0.0124	0.133	CbGeAlD
Canagliflozin—CYP3A4—Doxorubicin—liver cancer	0.0112	0.0266	CbGbCtD
Canagliflozin—ABCC2—bile—liver cancer	0.0102	0.109	CbGeAlD
Canagliflozin—ORM1—gall bladder—liver cancer	0.00343	0.0368	CbGeAlD
Canagliflozin—Dapagliflozin—CYP1A1—liver cancer	0.00306	1	CrCbGaD
Canagliflozin—ALB—gall bladder—liver cancer	0.00301	0.0323	CbGeAlD
Canagliflozin—UGT2B4—liver—liver cancer	0.0028	0.03	CbGeAlD
Canagliflozin—UGT1A9—liver—liver cancer	0.00191	0.0205	CbGeAlD
Canagliflozin—Rash papular—Epirubicin—liver cancer	0.00125	0.0266	CcSEcCtD
Canagliflozin—Rash papular—Doxorubicin—liver cancer	0.00115	0.0246	CcSEcCtD
Canagliflozin—ORM1—liver—liver cancer	0.00101	0.0108	CbGeAlD
Canagliflozin—Renal failure acute—Sorafenib—liver cancer	0.000988	0.0211	CcSEcCtD
Canagliflozin—Vulvovaginal candidiasis—Epirubicin—liver cancer	0.000883	0.0188	CcSEcCtD
Canagliflozin—ALB—liver—liver cancer	0.000883	0.00946	CbGeAlD
Canagliflozin—Vulvovaginal mycotic infection—Epirubicin—liver cancer	0.000849	0.0181	CcSEcCtD
Canagliflozin—Dehydration—Sorafenib—liver cancer	0.000848	0.0181	CcSEcCtD
Canagliflozin—ABCC2—liver—liver cancer	0.000827	0.00886	CbGeAlD
Canagliflozin—Breast disorder—Sorafenib—liver cancer	0.000824	0.0176	CcSEcCtD
Canagliflozin—Vulvovaginal candidiasis—Doxorubicin—liver cancer	0.000817	0.0174	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Doxorubicin—liver cancer	0.000786	0.0168	CcSEcCtD
Canagliflozin—Pancreatitis—Sorafenib—liver cancer	0.000773	0.0165	CcSEcCtD
Canagliflozin—Serum creatinine increased—Epirubicin—liver cancer	0.000755	0.0161	CcSEcCtD
Canagliflozin—Serum creatinine increased—Doxorubicin—liver cancer	0.000699	0.0149	CcSEcCtD
Canagliflozin—ABCB1—embryo—liver cancer	0.000643	0.00689	CbGeAlD
Canagliflozin—Urinary tract disorder—Sorafenib—liver cancer	0.000623	0.0133	CcSEcCtD
Canagliflozin—Urethral disorder—Sorafenib—liver cancer	0.000619	0.0132	CcSEcCtD
Canagliflozin—Rash erythematous—Epirubicin—liver cancer	0.000606	0.0129	CcSEcCtD
Canagliflozin—Rash pustular—Epirubicin—liver cancer	0.000582	0.0124	CcSEcCtD
Canagliflozin—Angiopathy—Sorafenib—liver cancer	0.000573	0.0122	CcSEcCtD
Canagliflozin—Rash erythematous—Doxorubicin—liver cancer	0.000561	0.012	CcSEcCtD
Canagliflozin—Malnutrition—Sorafenib—liver cancer	0.000549	0.0117	CcSEcCtD
Canagliflozin—Erythema—Sorafenib—liver cancer	0.000549	0.0117	CcSEcCtD
Canagliflozin—Rash pustular—Doxorubicin—liver cancer	0.000539	0.0115	CcSEcCtD
Canagliflozin—Angioedema—Sorafenib—liver cancer	0.000502	0.0107	CcSEcCtD
Canagliflozin—Nocturia—Epirubicin—liver cancer	0.000501	0.0107	CcSEcCtD
Canagliflozin—Syncope—Sorafenib—liver cancer	0.000493	0.0105	CcSEcCtD
Canagliflozin—Loss of consciousness—Sorafenib—liver cancer	0.000483	0.0103	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000464	0.0099	CcSEcCtD
Canagliflozin—Nocturia—Doxorubicin—liver cancer	0.000463	0.00987	CcSEcCtD
Canagliflozin—Dry mouth—Sorafenib—liver cancer	0.000457	0.00975	CcSEcCtD
Canagliflozin—Hyperkalaemia—Epirubicin—liver cancer	0.000456	0.00973	CcSEcCtD
Canagliflozin—Cystitis noninfective—Epirubicin—liver cancer	0.000454	0.00967	CcSEcCtD
Canagliflozin—Cystitis—Epirubicin—liver cancer	0.000448	0.00956	CcSEcCtD
Canagliflozin—Infection—Sorafenib—liver cancer	0.000445	0.00949	CcSEcCtD
Canagliflozin—Shock—Sorafenib—liver cancer	0.000441	0.0094	CcSEcCtD
Canagliflozin—Nervous system disorder—Sorafenib—liver cancer	0.00044	0.00937	CcSEcCtD
Canagliflozin—Vaginal infection—Epirubicin—liver cancer	0.000438	0.00935	CcSEcCtD
Canagliflozin—Blood urea increased—Epirubicin—liver cancer	0.000438	0.00935	CcSEcCtD
Canagliflozin—Skin disorder—Sorafenib—liver cancer	0.000435	0.00928	CcSEcCtD
Canagliflozin—Hyperkalaemia—Doxorubicin—liver cancer	0.000422	0.009	CcSEcCtD
Canagliflozin—Rash maculo-papular—Epirubicin—liver cancer	0.000422	0.009	CcSEcCtD
Canagliflozin—CYP3A4—liver—liver cancer	0.00042	0.0045	CbGeAlD
Canagliflozin—Bladder pain—Epirubicin—liver cancer	0.00042	0.00895	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—liver cancer	0.00042	0.00895	CcSEcCtD
Canagliflozin—Cystitis—Doxorubicin—liver cancer	0.000415	0.00884	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—liver cancer	0.000406	0.00865	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—liver cancer	0.000406	0.00865	CcSEcCtD
Canagliflozin—Rash maculo-papular—Doxorubicin—liver cancer	0.000391	0.00833	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—liver cancer	0.000388	0.00828	CcSEcCtD
Canagliflozin—Diabetes mellitus—Epirubicin—liver cancer	0.000388	0.00826	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Sorafenib—liver cancer	0.000387	0.00825	CcSEcCtD
Canagliflozin—Fatigue—Sorafenib—liver cancer	0.000387	0.00824	CcSEcCtD
Canagliflozin—Photosensitivity—Epirubicin—liver cancer	0.000384	0.00818	CcSEcCtD
Canagliflozin—Constipation—Sorafenib—liver cancer	0.000383	0.00817	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Sorafenib—liver cancer	0.000367	0.00781	CcSEcCtD
Canagliflozin—Renal failure acute—Epirubicin—liver cancer	0.000365	0.00778	CcSEcCtD
Canagliflozin—Diabetes mellitus—Doxorubicin—liver cancer	0.000359	0.00764	CcSEcCtD
Canagliflozin—Urticaria—Sorafenib—liver cancer	0.000356	0.00759	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—liver cancer	0.000355	0.00757	CcSEcCtD
Canagliflozin—Abdominal pain—Sorafenib—liver cancer	0.000354	0.00755	CcSEcCtD
Canagliflozin—Hypoglycaemia—Epirubicin—liver cancer	0.000345	0.00736	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—liver cancer	0.000338	0.0072	CcSEcCtD
Canagliflozin—Hypersensitivity—Sorafenib—liver cancer	0.00033	0.00704	CcSEcCtD
Canagliflozin—Asthenia—Sorafenib—liver cancer	0.000322	0.00686	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—liver cancer	0.00032	0.00681	CcSEcCtD
Canagliflozin—Pruritus—Sorafenib—liver cancer	0.000317	0.00676	CcSEcCtD
Canagliflozin—Blood creatinine increased—Epirubicin—liver cancer	0.000316	0.00673	CcSEcCtD
Canagliflozin—Dehydration—Epirubicin—liver cancer	0.000314	0.00668	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Epirubicin—liver cancer	0.000308	0.00656	CcSEcCtD
Canagliflozin—Breast disorder—Epirubicin—liver cancer	0.000305	0.00649	CcSEcCtD
Canagliflozin—ABCB1—liver—liver cancer	0.000297	0.00319	CbGeAlD
Canagliflozin—Dizziness—Sorafenib—liver cancer	0.000296	0.00632	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—liver cancer	0.000292	0.00623	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—liver cancer	0.00029	0.00618	CcSEcCtD
Canagliflozin—Pancreatitis—Epirubicin—liver cancer	0.000286	0.00609	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—liver cancer	0.000285	0.00607	CcSEcCtD
Canagliflozin—Rash—Sorafenib—liver cancer	0.000283	0.00603	CcSEcCtD
Canagliflozin—Dermatitis—Sorafenib—liver cancer	0.000282	0.00602	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—liver cancer	0.000282	0.00601	CcSEcCtD
Canagliflozin—Pollakiuria—Epirubicin—liver cancer	0.000269	0.00574	CcSEcCtD
Canagliflozin—Nausea—Sorafenib—liver cancer	0.000266	0.00568	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Epirubicin—liver cancer	0.000266	0.00567	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—liver cancer	0.000264	0.00563	CcSEcCtD
Canagliflozin—Urinary tract infection—Epirubicin—liver cancer	0.000253	0.00538	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—liver cancer	0.000249	0.00531	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—liver cancer	0.000246	0.00525	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—liver cancer	0.000234	0.00498	CcSEcCtD
Canagliflozin—Urinary tract disorder—Epirubicin—liver cancer	0.00023	0.00491	CcSEcCtD
Canagliflozin—Urethral disorder—Epirubicin—liver cancer	0.000229	0.00487	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—liver cancer	0.000213	0.00454	CcSEcCtD
Canagliflozin—Angiopathy—Epirubicin—liver cancer	0.000212	0.00451	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—liver cancer	0.000212	0.00451	CcSEcCtD
Canagliflozin—Erythema—Epirubicin—liver cancer	0.000203	0.00433	CcSEcCtD
Canagliflozin—Malnutrition—Epirubicin—liver cancer	0.000203	0.00433	CcSEcCtD
Canagliflozin—Angiopathy—Doxorubicin—liver cancer	0.000196	0.00417	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—liver cancer	0.000188	0.004	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—liver cancer	0.000188	0.004	CcSEcCtD
Canagliflozin—Syncope—Epirubicin—liver cancer	0.000182	0.00388	CcSEcCtD
Canagliflozin—Loss of consciousness—Epirubicin—liver cancer	0.000178	0.0038	CcSEcCtD
Canagliflozin—Convulsion—Epirubicin—liver cancer	0.000176	0.00375	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000172	0.00366	CcSEcCtD
Canagliflozin—Dry mouth—Epirubicin—liver cancer	0.000169	0.0036	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—liver cancer	0.000168	0.00359	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—liver cancer	0.000165	0.00352	CcSEcCtD
Canagliflozin—Infection—Epirubicin—liver cancer	0.000165	0.00351	CcSEcCtD
Canagliflozin—Shock—Epirubicin—liver cancer	0.000163	0.00347	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—liver cancer	0.000163	0.00347	CcSEcCtD
Canagliflozin—Nervous system disorder—Epirubicin—liver cancer	0.000162	0.00346	CcSEcCtD
Canagliflozin—Skin disorder—Epirubicin—liver cancer	0.000161	0.00343	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000159	0.00339	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—liver cancer	0.000156	0.00333	CcSEcCtD
Canagliflozin—Hypotension—Epirubicin—liver cancer	0.000155	0.0033	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—liver cancer	0.000152	0.00325	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—liver cancer	0.000151	0.00322	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—liver cancer	0.00015	0.0032	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—liver cancer	0.000149	0.00317	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—liver cancer	0.000143	0.00305	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Epirubicin—liver cancer	0.000143	0.00305	CcSEcCtD
Canagliflozin—Fatigue—Epirubicin—liver cancer	0.000143	0.00305	CcSEcCtD
Canagliflozin—Constipation—Epirubicin—liver cancer	0.000142	0.00302	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Epirubicin—liver cancer	0.000135	0.00289	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000132	0.00282	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—liver cancer	0.000132	0.00282	CcSEcCtD
Canagliflozin—Urticaria—Epirubicin—liver cancer	0.000132	0.00281	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—liver cancer	0.000131	0.00279	CcSEcCtD
Canagliflozin—Abdominal pain—Epirubicin—liver cancer	0.000131	0.00279	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—liver cancer	0.000125	0.00267	CcSEcCtD
Canagliflozin—Hypersensitivity—Epirubicin—liver cancer	0.000122	0.0026	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—liver cancer	0.000122	0.0026	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—liver cancer	0.000121	0.00258	CcSEcCtD
Canagliflozin—Asthenia—Epirubicin—liver cancer	0.000119	0.00253	CcSEcCtD
Canagliflozin—Pruritus—Epirubicin—liver cancer	0.000117	0.0025	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—liver cancer	0.000113	0.00241	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—liver cancer	0.00011	0.00234	CcSEcCtD
Canagliflozin—Dizziness—Epirubicin—liver cancer	0.00011	0.00234	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—liver cancer	0.000108	0.00231	CcSEcCtD
Canagliflozin—Rash—Epirubicin—liver cancer	0.000104	0.00223	CcSEcCtD
Canagliflozin—Dermatitis—Epirubicin—liver cancer	0.000104	0.00222	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—liver cancer	0.000101	0.00216	CcSEcCtD
Canagliflozin—Nausea—Epirubicin—liver cancer	9.84e-05	0.0021	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—liver cancer	9.67e-05	0.00206	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—liver cancer	9.66e-05	0.00206	CcSEcCtD
Canagliflozin—Nausea—Doxorubicin—liver cancer	9.11e-05	0.00194	CcSEcCtD
Canagliflozin—SLC5A1—Disease—CTNNB1—liver cancer	3.6e-05	0.000223	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CDKN1A—liver cancer	3.52e-05	0.000218	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDKN1A—liver cancer	3.52e-05	0.000218	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTA1—liver cancer	3.5e-05	0.000217	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—EPT1—liver cancer	3.49e-05	0.000216	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TGFB1—liver cancer	3.48e-05	0.000216	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NAT2—liver cancer	3.46e-05	0.000215	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL6—liver cancer	3.46e-05	0.000214	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CG—liver cancer	3.43e-05	0.000213	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK14—liver cancer	3.43e-05	0.000213	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GGT1—liver cancer	3.42e-05	0.000212	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—liver cancer	3.4e-05	0.000211	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CB—liver cancer	3.4e-05	0.000211	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CB—liver cancer	3.4e-05	0.000211	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	3.38e-05	0.000209	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.33e-05	0.000206	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—F2—liver cancer	3.32e-05	0.000206	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALDOB—liver cancer	3.32e-05	0.000206	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	3.31e-05	0.000205	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PPARG—liver cancer	3.31e-05	0.000205	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TAT—liver cancer	3.31e-05	0.000205	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	3.25e-05	0.000202	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—liver cancer	3.25e-05	0.000202	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—UGDH—liver cancer	3.25e-05	0.000202	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CG—liver cancer	3.18e-05	0.000197	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CRABP1—liver cancer	3.17e-05	0.000196	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—STAT3—liver cancer	3.14e-05	0.000195	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—STAT3—liver cancer	3.14e-05	0.000195	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	3.13e-05	0.000194	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—PPARA—liver cancer	3.09e-05	0.000191	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTP1—liver cancer	3.07e-05	0.000191	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—EPT1—liver cancer	3.06e-05	0.000189	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	3.03e-05	0.000188	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CD—liver cancer	3.01e-05	0.000187	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ALB—liver cancer	2.98e-05	0.000184	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—liver cancer	2.92e-05	0.000181	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—liver cancer	2.92e-05	0.000181	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TGFB1—liver cancer	2.91e-05	0.00018	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TGFB1—liver cancer	2.91e-05	0.00018	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TAT—liver cancer	2.9e-05	0.00018	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.85e-05	0.000177	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTM1—liver cancer	2.83e-05	0.000175	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	2.8e-05	0.000173	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CD—liver cancer	2.8e-05	0.000173	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA1—liver cancer	2.79e-05	0.000173	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	2.79e-05	0.000173	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HPGDS—liver cancer	2.77e-05	0.000172	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SERPINE1—liver cancer	2.76e-05	0.000171	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.75e-05	0.000171	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL6—liver cancer	2.75e-05	0.00017	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KRAS—liver cancer	2.7e-05	0.000167	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—KRAS—liver cancer	2.7e-05	0.000167	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP1A1—liver cancer	2.68e-05	0.000166	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	2.64e-05	0.000164	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CB—liver cancer	2.63e-05	0.000163	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.51e-05	0.000155	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—RAF1—liver cancer	2.5e-05	0.000155	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CA—liver cancer	2.48e-05	0.000154	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CA—liver cancer	2.48e-05	0.000154	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.47e-05	0.000153	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PRKCE—liver cancer	2.47e-05	0.000153	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PSMA4—liver cancer	2.47e-05	0.000153	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PSMD10—liver cancer	2.47e-05	0.000153	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	2.46e-05	0.000152	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	2.44e-05	0.000151	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—GGT1—liver cancer	2.43e-05	0.000151	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GOT2—liver cancer	2.4e-05	0.000149	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—CYCS—liver cancer	2.36e-05	0.000146	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ABL1—liver cancer	2.35e-05	0.000146	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF2—liver cancer	2.34e-05	0.000145	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ALB—liver cancer	2.29e-05	0.000142	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—liver cancer	2.29e-05	0.000142	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—liver cancer	2.29e-05	0.000142	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP2E1—liver cancer	2.26e-05	0.00014	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	2.25e-05	0.00014	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GLUL—liver cancer	2.25e-05	0.000139	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CPT1B—liver cancer	2.25e-05	0.000139	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—liver cancer	2.24e-05	0.000139	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HGF—liver cancer	2.21e-05	0.000137	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	2.21e-05	0.000137	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—liver cancer	2.19e-05	0.000136	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—liver cancer	2.19e-05	0.000136	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.18e-05	0.000135	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CSF2—liver cancer	2.18e-05	0.000135	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NR1H4—liver cancer	2.17e-05	0.000134	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	2.15e-05	0.000133	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	2.14e-05	0.000133	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTA3—liver cancer	2.13e-05	0.000132	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	2.13e-05	0.000132	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYCS—liver cancer	2.11e-05	0.000131	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	2.08e-05	0.000129	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—RAF1—liver cancer	2.08e-05	0.000129	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CA—liver cancer	2.07e-05	0.000129	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CA—liver cancer	2.07e-05	0.000129	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GOT1—liver cancer	2.07e-05	0.000128	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GGT1—liver cancer	2.07e-05	0.000128	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	2.07e-05	0.000128	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—HMOX1—liver cancer	2.05e-05	0.000127	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	2.03e-05	0.000126	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—liver cancer	2.02e-05	0.000125	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—liver cancer	2.02e-05	0.000125	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UGDH—liver cancer	2e-05	0.000124	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CPT1B—liver cancer	1.97e-05	0.000122	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GLUL—liver cancer	1.97e-05	0.000122	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTA4—liver cancer	1.95e-05	0.000121	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.91e-05	0.000118	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—liver cancer	1.9e-05	0.000118	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTA2—liver cancer	1.9e-05	0.000118	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NR1H4—liver cancer	1.9e-05	0.000118	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—EPT1—liver cancer	1.88e-05	0.000117	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	1.87e-05	0.000116	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA3—liver cancer	1.87e-05	0.000116	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTP1—liver cancer	1.86e-05	0.000115	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HMOX1—liver cancer	1.83e-05	0.000114	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTA1—liver cancer	1.83e-05	0.000114	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NAT2—liver cancer	1.81e-05	0.000112	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	1.8e-05	0.000111	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TAT—liver cancer	1.79e-05	0.000111	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK14—liver cancer	1.77e-05	0.00011	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—liver cancer	1.75e-05	0.000108	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.74e-05	0.000108	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDOB—liver cancer	1.74e-05	0.000108	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	1.72e-05	0.000107	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	1.72e-05	0.000107	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—F2—liver cancer	1.71e-05	0.000106	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—liver cancer	1.71e-05	0.000106	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA4—liver cancer	1.71e-05	0.000106	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—liver cancer	1.69e-05	0.000105	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—liver cancer	1.69e-05	0.000105	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA2—liver cancer	1.66e-05	0.000103	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CRABP1—liver cancer	1.66e-05	0.000103	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—PPARA—liver cancer	1.66e-05	0.000103	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CG—liver cancer	1.64e-05	0.000102	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1A1—liver cancer	1.62e-05	0.0001	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTA1—liver cancer	1.61e-05	9.95e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	1.6e-05	9.95e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—liver cancer	1.6e-05	9.93e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	1.59e-05	9.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NAT2—liver cancer	1.59e-05	9.84e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDOB—liver cancer	1.52e-05	9.44e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MTHFR—liver cancer	1.51e-05	9.36e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.49e-05	9.25e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	1.49e-05	9.21e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARA—liver cancer	1.48e-05	9.19e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	1.46e-05	9.07e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CRABP1—liver cancer	1.45e-05	9e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	1.45e-05	9e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HPGDS—liver cancer	1.45e-05	8.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CD—liver cancer	1.44e-05	8.93e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.44e-05	8.93e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SERPINE1—liver cancer	1.43e-05	8.83e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	1.41e-05	8.77e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.33e-05	8.25e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.31e-05	8.13e-05	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—liver cancer	1.31e-05	8.11e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PSMA4—liver cancer	1.29e-05	8e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PSMD10—liver cancer	1.29e-05	8e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RAF1—liver cancer	1.29e-05	7.97e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HPGDS—liver cancer	1.27e-05	7.87e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CG—liver cancer	1.27e-05	7.87e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GOT2—liver cancer	1.26e-05	7.79e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CB—liver cancer	1.26e-05	7.79e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—liver cancer	1.23e-05	7.59e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CPT1B—liver cancer	1.21e-05	7.52e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GLUL—liver cancer	1.21e-05	7.52e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	1.21e-05	7.52e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	1.19e-05	7.41e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2E1—liver cancer	1.18e-05	7.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NR1H4—liver cancer	1.17e-05	7.25e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—liver cancer	1.15e-05	7.15e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA3—liver cancer	1.15e-05	7.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.14e-05	7.09e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PSMA4—liver cancer	1.13e-05	7.01e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PSMD10—liver cancer	1.13e-05	7.01e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CD—liver cancer	1.12e-05	6.92e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	1.11e-05	6.9e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYCS—liver cancer	1.1e-05	6.85e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—liver cancer	1.1e-05	6.83e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GOT2—liver cancer	1.1e-05	6.82e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GOT1—liver cancer	1.08e-05	6.72e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GGT1—liver cancer	1.08e-05	6.72e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	1.08e-05	6.69e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA4—liver cancer	1.05e-05	6.52e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2E1—liver cancer	1.03e-05	6.41e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA2—liver cancer	1.03e-05	6.36e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTA1—liver cancer	9.89e-06	6.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—liver cancer	9.8e-06	6.08e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NAT2—liver cancer	9.78e-06	6.06e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	9.76e-06	6.05e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTP1—liver cancer	9.74e-06	6.04e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CB—liver cancer	9.73e-06	6.03e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYCS—liver cancer	9.68e-06	6e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMOX1—liver cancer	9.61e-06	5.95e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GGT1—liver cancer	9.5e-06	5.89e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GOT1—liver cancer	9.5e-06	5.89e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDOB—liver cancer	9.38e-06	5.81e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—liver cancer	9e-06	5.58e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—liver cancer	8.95e-06	5.55e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CRABP1—liver cancer	8.95e-06	5.55e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTP1—liver cancer	8.53e-06	5.29e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1A1—liver cancer	8.48e-06	5.26e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMOX1—liver cancer	8.42e-06	5.22e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—liver cancer	8.33e-06	5.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTHFR—liver cancer	7.91e-06	4.9e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—liver cancer	7.84e-06	4.86e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HPGDS—liver cancer	7.82e-06	4.85e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARA—liver cancer	7.76e-06	4.81e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—liver cancer	7.66e-06	4.75e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1A1—liver cancer	7.43e-06	4.61e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—liver cancer	7.41e-06	4.59e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—liver cancer	7.08e-06	4.39e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.97e-06	4.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PSMA4—liver cancer	6.97e-06	4.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PSMD10—liver cancer	6.97e-06	4.32e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTHFR—liver cancer	6.93e-06	4.3e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARA—liver cancer	6.8e-06	4.21e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GOT2—liver cancer	6.78e-06	4.2e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CG—liver cancer	6.65e-06	4.12e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—liver cancer	6.41e-06	3.98e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2E1—liver cancer	6.37e-06	3.95e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—liver cancer	6.25e-06	3.88e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYCS—liver cancer	5.96e-06	3.7e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—liver cancer	5.93e-06	3.68e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GOT1—liver cancer	5.85e-06	3.63e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GGT1—liver cancer	5.85e-06	3.63e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CD—liver cancer	5.84e-06	3.62e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CG—liver cancer	5.82e-06	3.61e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—liver cancer	5.62e-06	3.48e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTP1—liver cancer	5.26e-06	3.26e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMOX1—liver cancer	5.18e-06	3.21e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CD—liver cancer	5.12e-06	3.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CB—liver cancer	5.09e-06	3.16e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—liver cancer	5.05e-06	3.13e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—liver cancer	4.84e-06	3e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—liver cancer	4.83e-06	2.99e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1A1—liver cancer	4.58e-06	2.84e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CB—liver cancer	4.46e-06	2.77e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTHFR—liver cancer	4.27e-06	2.65e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARA—liver cancer	4.19e-06	2.6e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CG—liver cancer	3.59e-06	2.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—liver cancer	3.46e-06	2.15e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CD—liver cancer	3.15e-06	1.95e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—liver cancer	3.11e-06	1.93e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—liver cancer	3.1e-06	1.92e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CB—liver cancer	2.75e-06	1.7e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—liver cancer	2.72e-06	1.69e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—liver cancer	2.54e-06	1.57e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—liver cancer	2.22e-06	1.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—liver cancer	1.68e-06	1.04e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—liver cancer	1.37e-06	8.49e-06	CbGpPWpGaD
